Osteoporozda antirezorptif tedavinin osteopontin değerleri üzerine etkisi

Amaç: Yüksek osteopontin (OPN) seviyelerinin kemik rezorpsiyonu ile ilişkili olduğu bildirilmiştir. Osteoporozda (OP) anabolik etki amacıyla uygulanan parathormonun, OPN düzeylerinde düşmeye neden olduğu tespit edilmiştir. Bu çalışmanın amacı OP tedavisi için antirezorptif tedavi alan hastalarda OPN düzeylerinin değerlendirilmesidir. Materyal ve metot: Çalışmamıza, 45-70 yaş arası, en az bir yıldır menopoza girmiş, OP tanısı alan 90 kadın hasta ve 80 sağlıklı kadın gönüllü dahil edildi. OP hastaları antirezorptif kullanan (60 hasta;15 bifosfonat, 15 kalsitonin, 15 raloksifen, 15 strontium ranelate kullanan hasta) ve kullanmayanlar (30 hasta) olmak üzere iki gruba ayrıldı. Hastalara KMY ölçümü, DEXA (Dual Enerji X-Ray Absorbsiyometri) yöntemi ile yapıldı. Plazma OPN konsantrasyonu enzyme-link immunosorbent assay (ELISA) methodu kullanılarak hesaplandı. Bulgular: Antirezorptif kullanan OP grubunda OPN düzeyleri, antirezorptif almayan OP grubuna ve OP olmayan sağlıklı kontrol grubuna göre istatistiksel olarak anlamlı düzeyde daha düşüktü (sırasıyla p0.05). Sonuç: Sonuçlarımızın, antirezorptif tedavinin OPN seviyelerinde düşmeye neden olduğunu göstermesi, bize OPN'nin, antirezorptif tedavinin takibinde bir biomarker olarak kullanılabileceğini düşündürdü.Background: An association between increased OPN levels and lowered bone mineral density (BMD) with increased bone turnover markers was established. The aim of this study is to evaluate the levels of OPN in OP patients who receive antiresorptive treatment (ART). Methods: Ninety female OP patients in the post-menopausal period for at least a year in the age range of 45 - 70 years and 80 healthy female volunteers were included in the study. OP patients were divided into 2 subgroups as ART-receiving (60 patients; bisphosphonate (15), calcitonin (15), raloxifene (15), strontium ranelate (15) and ART non-receiving (30 patients). Bone mineral density was analyzed using the dual energy X-ray absorptiometry method. The plasma OPN concentration was calculated using the enzyme-link immunosorbent assay method. Result s : OPN levels were significantly lower in antiresorptive-receiving OP patients compared to OP patients who did not receive ART and compared to the control group (p<0.001 and p=0.008 respectively). There was no meaningful difference in terms of the OPN values between the controls and OP patients who did not receive ART (p>0.05). Conclusions: Lowered OPN levels in ART-receiving OP patients suggest that OPN could be used as a biomarker in ART follow-up in OP

Endothelial nitric oxide synthase gene polymorphisms associated with periodontal diseases in Turkish adults

Endothelial nitric oxide synthase (NOS3) is involved in key steps of immune response. Genetic factors predispose individuals to periodontal disease. This study's aim was to explore the association between NOS3 gene polymorphisms and clinical parameters in patients with periodontal disease. Genomic DNA was obtained from the peripheral blood of 23 subjects with aggressive periodontitis (AgP), 26 with chronic periodontitis (CP), 31 with gingivitis (G) and 50 healthy controls. Probing depth (PD), clinical attachment loss (CAL), plaque index (PI) and gingival index (GI) were recorded as clinical parameters. We genotyped NOS3 polymorphisms using the PCR and/or PCR-RFLP method. Genotype frequencies differed significantly among periodontal diseases and controls for these polymorphisms. A significant association was detected between NOS3 +894 polymorphism and PD and CAL in the CP and AgP patient groups; whereas NOS VNTR analysis detected no associations with clinical parameters in the CP and AgP groups. However, a significant association was detected between the AA genotype and both PI and GI in patients with gingivitis; and a significant association was shown between the BB genotype and PI. The present study shows that two common polymorphisms of the NOS3 gene cluster are significantly associated with the occurrence of periodontal diseases

Meme kanserli hastalarda PARP1 gen ekspresyonu

Poli (ADP riboz) polimeraz (PARP), DNA onarım mekanizmasında yer alan bir enzim ailesidir. Bu enzimlerden PARP1, baz kesip- çıkarma onarım (BER) mekanizmasına öncülük eden tek zincir DNA kırıklarının saptanmasında rol alır. BRCA1 ve BRCA2 genlerinden yoksun meme kanseri tümörleri, DNA çift zincir kırıklarının onarımında yetersizdirler. PARP enzimlerinin bu tümörlerdeki aktivitesi ilgi konusudur çünkü PARP aktivitesinin kaybı, tek zincir DNA kırıklarının birikimine, biriken tek zincir DNA kırıklarının çift zincir DNA kırıklarına dönüşmesine ve takiben tamir edilemeyen DNA hasarı ve hücre ölümüne yol açmaktadır. Bu yüzden PARP inhibisyonunun, kanser hücrelerini öldürmede etkili olabileceği düşünülmekte ve PARP inhibitörlerinin seçici olarak meme kanseri tümörlerini öldürmedeki etkinliği araştırılmaktadır. Bu çalışmada, PARP inhibitörlerinin meme kanserine karşı kullanılma potansiyelinin değerlendirilmesi için bir grup meme kanserli hastada, PARP-1 gen ifade düzeyi ve kanser markırlarından östrojen reseptörü (ER), progesteron reseptörü (PR) ve insan epidermal büyüme faktör reseptörü 2 (HER2)’nin gen ifade düzeyleri belirlenmiştir. Hastalarda PARP-1 gen ifade düzeyinin meme kanseri oluşumu ile ilişkili olmadığı gösterilmiştir.Poly (ADP-ribose) polymerase (PARP) family of enzymes is part of the DNA repair mechanism. One of these enzymes, PARP-1 is involved in detection of signal single-strand DNA breaks (SSBs) that leads to base excision repair (BER) mechanism. Breast cancer tumors that lack Breast cancer susceptibility gene 1 (BRCA1) and Breast cancer susceptibility gene 2 (BRCA2) are ineffective in DNA double-strand breaks (DSB) repair. Activity of the poly (ADP-ribose) polymerase (PARP) enzymes in these tumors is of interest as a lack of PARP activity leads to accumulation of SSBs that are converted to DSBs and accumulation of DSBs lead to irreparable DNA damage and cell death. Therefore inhibition of PARP in tumor cells might be effective in killing cancer tumors and activity of PARP inhibitors in selectively killing breast cancer tumors is currently being evaluated. In this study, expression of PARP-1 and cancer markers estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) were determined in a group of breast cancer patients to assess the potential for using PARP inhibitors against this form of cancer. Expression of PARP- 1 was found not to correlate with the onset of breast cancer in the patients